CANF
Price
$0.65
Change
-$0.00 (-0.00%)
Updated
Sep 5 closing price
Capitalization
14.08M
OTLC
Price
$0.05
Change
-$0.00 (-0.00%)
Updated
Sep 5 closing price
Capitalization
22.83M
79 days until earnings call
Interact to see
Advertisement

CANF vs OTLC

Header iconCANF vs OTLC Comparison
Open Charts CANF vs OTLCBanner chart's image
Can-Fite BioPharma
Price$0.65
Change-$0.00 (-0.00%)
Volume$99.25K
Capitalization14.08M
Oncotelic Therapeutics
Price$0.05
Change-$0.00 (-0.00%)
Volume$2.8K
Capitalization22.83M
CANF vs OTLC Comparison Chart in %
Loading...
CANF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OTLC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CANF vs. OTLC commentary
Sep 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CANF is a StrongBuy and OTLC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 07, 2025
Stock price -- (CANF: $0.65 vs. OTLC: $0.05)
Brand notoriety: CANF and OTLC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CANF: 48% vs. OTLC: 3%
Market capitalization -- CANF: $14.08M vs. OTLC: $22.83M
CANF [@Biotechnology] is valued at $14.08M. OTLC’s [@Biotechnology] market capitalization is $22.83M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CANF’s FA Score shows that 1 FA rating(s) are green whileOTLC’s FA Score has 0 green FA rating(s).

  • CANF’s FA Score: 1 green, 4 red.
  • OTLC’s FA Score: 0 green, 5 red.
According to our system of comparison, OTLC is a better buy in the long-term than CANF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CANF’s TA Score shows that 5 TA indicator(s) are bullish while OTLC’s TA Score has 6 bullish TA indicator(s).

  • CANF’s TA Score: 5 bullish, 3 bearish.
  • OTLC’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, OTLC is a better buy in the short-term than CANF.

Price Growth

CANF (@Biotechnology) experienced а +3.17% price change this week, while OTLC (@Biotechnology) price change was -1.32% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

OTLC is expected to report earnings on Nov 24, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OTLC($22.8M) has a higher market cap than CANF($14.1M). OTLC YTD gains are higher at: 50.000 vs. CANF (-59.914). CANF has more cash in the bank: 995K vs. OTLC (88K). CANF has less debt than OTLC: CANF (40K) vs OTLC (13.5M).
CANFOTLCCANF / OTLC
Capitalization14.1M22.8M62%
EBITDAN/A-3.36M-
Gain YTD-59.91450.000-120%
P/E RatioN/AN/A-
RevenueN/A0-
Total Cash995K88K1,131%
Total Debt40K13.5M0%
FUNDAMENTALS RATINGS
CANF vs OTLC: Fundamental Ratings
CANF
OTLC
OUTLOOK RATING
1..100
6656
VALUATION
overvalued / fair valued / undervalued
1..100
29
Undervalued
49
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9997
PRICE GROWTH RATING
1..100
9349
P/E GROWTH RATING
1..100
10095
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CANF's Valuation (29) in the Biotechnology industry is in the same range as OTLC (49) in the null industry. This means that CANF’s stock grew similarly to OTLC’s over the last 12 months.

CANF's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as OTLC (100) in the null industry. This means that CANF’s stock grew similarly to OTLC’s over the last 12 months.

OTLC's SMR Rating (97) in the null industry is in the same range as CANF (99) in the Biotechnology industry. This means that OTLC’s stock grew similarly to CANF’s over the last 12 months.

OTLC's Price Growth Rating (49) in the null industry is somewhat better than the same rating for CANF (93) in the Biotechnology industry. This means that OTLC’s stock grew somewhat faster than CANF’s over the last 12 months.

OTLC's P/E Growth Rating (95) in the null industry is in the same range as CANF (100) in the Biotechnology industry. This means that OTLC’s stock grew similarly to CANF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CANFOTLC
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 10 days ago
79%
Bullish Trend 9 days ago
81%
Declines
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
76%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CANF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OTLC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DIIBF0.95N/A
+0.38%
Dorel Industries, Inc.
BKRIY15.130.03
+0.20%
Bank Ireland Group PLC
PHPRF1.24N/A
N/A
Primary Health Properties Plc.
CRSF0.35N/A
N/A
Crisp Momentum Inc.
MHIFF0.06N/A
N/A
Mineral Hill Industries Ltd.

CANF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CANF has been loosely correlated with OABI. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if CANF jumps, then OABI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CANF
1D Price
Change %
CANF100%
-0.05%
OABI - CANF
34%
Loosely correlated
+6.88%
ASMB - CANF
27%
Poorly correlated
+2.17%
CYTK - CANF
27%
Poorly correlated
+6.55%
RNA - CANF
27%
Poorly correlated
+3.90%
IVF - CANF
26%
Poorly correlated
-2.90%
More

OTLC and

Correlation & Price change

A.I.dvisor tells us that OTLC and THAR have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that OTLC and THAR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OTLC
1D Price
Change %
OTLC100%
+10.06%
THAR - OTLC
25%
Poorly correlated
-7.77%
DRUG - OTLC
20%
Poorly correlated
-3.89%
CANF - OTLC
20%
Poorly correlated
-0.05%
MMIRF - OTLC
15%
Poorly correlated
N/A
NDTP - OTLC
2%
Poorly correlated
N/A
More